Impact BioMedical, Inc. (IBO) Income Statement
IBO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIBO revenue and net income
Where IBO's revenue goes
2025Each bar shows an amount and its share of revenue. IBO kept −36,993.8% of revenue as net income.
IBO profit margins
IBO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −98.0% | −13.8% | — | — |
| Gross profit | −124.2% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | −133.9% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IBO quarterly EPS vs estimates
Next report: November 6, 2026.
IBO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $32,000 | $1.6M | $1.0M | $50,000 | $50,000 | $0 | $0 | $0 | $0 |
| Cost of revenue | $424,000 | $1.1M | $1.1M | $1.1M | $1.1M | — | — | — | — |
| Gross profit | −$392,000 | $1.6M | −$1.1M | $50,000 | $50,000 | — | — | — | — |
| Research & development | $340,000 | $278,000 | $1.7M | $1.2M | $1.2M | $513,692 | $442,302 | — | — |
| Sales, general & admin | $2.0M | $1.8M | $1.1M | $1.4M | $1.4M | $383,422 | $237,723 | $68,850 | $176,229 |
| Total operating expenses | $3.9M | $28.8M | $4.0M | $3.5M | $3.5M | $896,727 | $680,025 | $68,850 | $176,229 |
| Operating income | −$4.3M | −$28.8M | −$4.0M | −$3.4M | −$3.4M | −$896,727 | −$680,025 | −$33,861 | $63,952 |
| Interest income | $13,000 | $13,000 | $13,000 | $24,000 | $24,000 | — | — | — | — |
| Interest expense | $793,000 | $117,401 | $444,000 | $462,000 | $300,000 | — | — | — | — |
| Income before taxes | −$14.4M | −$24.7M | −$4.4M | −$7.9M | −$7.9M | −$896,727 | −$849,238 | −$98,109 | −$408,289 |
| Income taxes | −$2.6M | $33,000 | — | −$621,000 | −$621,000 | −$82,000 | $59,065 | — | — |
| Net income | −$11.8M | −$24.7M | −$4.3M | −$7.1M | −$7.1M | −$597,342 | −$590,080 | −$98,109 | −$408,289 |
| EBITDA | −$12.5M | −$22.6M | −$2.8M | −$6.3M | −$6.3M | −$896,727 | $638 | −$33,861 | $63,952 |
| EPS (diluted) | −$0.78 | $2.30 | −$4.76 | −$7.73 | −$7.73 | −$0.66 | −$0.05 | −$0.01 | −$0.04 |
| Gross margin | −1,225.0% | 100.0% | −108.7% | 100.0% | 100.0% | — | — | — | — |
| Operating margin | −13,343.8% | −1,775.1% | −391.1% | −6,808.0% | −6,808.0% | — | — | — | — |
| Net margin | −36,993.8% | −1,525.3% | −421.0% | −14,102.0% | −14,102.0% | — | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3,000 | $7,000 | $7,000 | $18,000 | $7,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1,000 | $285,000 | $422,000 | $1,000 | $1,000 | $283,000 | $279,000 | $281,000 | $279,000 | $280,000 | $280,000 | $280,000 |
| Gross profit | $2,000 | $7,000 | −$415,000 | $17,000 | $6,000 | −$283,000 | −$279,000 | −$281,000 | −$279,000 | −$280,000 | −$280,000 | −$280,000 |
| Research & development | $76,000 | $46,000 | $110,000 | $52,000 | $75,000 | $103,000 | $108,000 | $82,000 | $121,000 | $183,000 | $463,000 | $239,000 |
| Sales, general & admin | $277,000 | $1.9M | $275,000 | $516,000 | $676,000 | $509,000 | $591,000 | $719,000 | $214,000 | $305,000 | $274,000 | $454 |
| Total operating expenses | $704,000 | $2.3M | $743,000 | $965,000 | $1.2M | $1.0M | $26.2M | $1.1M | $347,000 | $491,000 | $859,000 | $798,000 |
| Operating income | −$702,000 | −$2.3M | −$1.2M | −$948,000 | −$1.2M | −$1.0M | −$26.2M | −$1.1M | −$626,000 | −$771,000 | −$1.1M | −$1.1M |
| Interest income | $2,000 | $5,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 | $3,000 |
| Interest expense | $0 | $0 | $1.6M | $262,000 | $260,000 | $271,000 | $270,000 | $305,000 | $261,000 | $230,000 | $125,000 | $102,000 |
| Income before taxes | −$700,000 | −$2.3M | $2.7M | −$1.5M | −$14.4M | −$1.3M | −$27.1M | $4.2M | −$884,000 | −$998,000 | −$1.3M | −$1.2M |
| Income taxes | −$1,000 | $3,000 | −$2.6M | −$5,000 | — | — | $33,000 | — | — | — | — | — |
| Net income | −$699,000 | −$2.3M | $5.2M | −$1.5M | −$14.3M | −$1.3M | −$27.1M | $4.2M | −$889,000 | −$962,000 | −$1.2M | −$1.2M |
| EBITDA | −$418,000 | −$2.0M | $2.9M | −$925,000 | −$13.8M | −$724,000 | −$26.6M | $4.8M | −$347,000 | −$491,000 | −$859,000 | −$798,000 |
| EPS (diluted) | −$0.01 | −$0.27 | $0.63 | −$0.12 | −$1.18 | −$0.11 | −$2.36 | $4.66 | — | — | — | — |
| Gross margin | 66.7% | 100.0% | −5,928.6% | 94.4% | 85.7% | — | — | — | — | — | — | — |
| Operating margin | −23,400.0% | −32,700.0% | −16,542.9% | −5,266.7% | −16,471.4% | — | — | — | — | — | — | — |
| Net margin | −23,300.0% | −32,671.4% | 74,928.6% | −8,166.7% | −204,942.9% | — | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IBO's financial statements (latest annual report filed March 11, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IBO financial results
In fiscal year 2025 (ended December 31, 2025), Impact BioMedical reported revenue of $0.0 million, down 98.0% from the year before. It had a net loss of $11.8 million, a net profit margin of −36,993.8%. Diluted earnings per share came to −$0.78.
See the IBO stock overview for the latest quote and news, or the IBO chart for price history and technical indicators.
IBO income statement FAQ
What is Impact BioMedical's annual revenue?
Impact BioMedical reported total revenue of $0.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 98.0% from $1.6 million the previous year.
Is Impact BioMedical profitable?
No. Impact BioMedical reported a net loss of $11.8 million in fiscal 2025, a net profit margin of −36,993.8%; its operating margin was −13,343.8%.
What is Impact BioMedical's gross margin?
Impact BioMedical's gross margin was −1,225.0% in fiscal 2025: for every $100 of revenue, Impact BioMedical kept $-1225 after the direct cost of its products and services.
How much does Impact BioMedical spend on research and development?
Impact BioMedical spent $0.3 million on research and development in fiscal 2025, 1,062.5% of revenue.
What are Impact BioMedical's earnings per share?
Impact BioMedical earned $-0.78 per diluted share in fiscal 2025, compared with $2.30 a year earlier.
When will Impact BioMedical report its next earnings?
Impact BioMedical is expected to report results for the quarter ending September 30, 2026 on November 6, 2026.
When does Impact BioMedical's fiscal year end?
Impact BioMedical's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 11, 2026.